Asian Pacific Journal of Cancer Prevention

  • 제15권2호
  • /
  • Pages.657-662
  • /
  • 2014
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

Relationships between EGFR Mutation Status of Lung Cancer and Preoperative Factors - Are they Predictive?

  • Usuda, Katsuo (Department of Thoracic Surgery, Kanazawa Medical University) ;
  • Sagawa, Motoyasu (Department of Thoracic Surgery, Kanazawa Medical University) ;
  • Motono, Nozomu (Department of Thoracic Surgery, Kanazawa Medical University) ;
  • Ueno, Masakatsu (Department of Thoracic Surgery, Kanazawa Medical University) ;
  • Tanaka, Makoto (Department of Thoracic Surgery, Kanazawa Medical University) ;
  • Machida, Yuichiro (Department of Thoracic Surgery, Kanazawa Medical University) ;
  • Matoba, Munetaka (Department of Radiology, Kanazawa Medical University) ;
  • Taniguchi, Mitsuru (Department of Radiology, Kanazawa Medical University) ;
  • Tonami, Hisao (Department of Radiology, Kanazawa Medical University) ;
  • Ueda, Yoshimichi (Department of Pathophysiological and Experimental Pathology, Kanazawa Medical University) ;
  • Sakuma, Tsutomu (Department of Thoracic Surgery, Kanazawa Medical University)
  • 발행 : 2014.01.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background: The epidermal growth factor receptor (EGFR) mutation status of lung cancer is important because it means that EGFR-tyrosine kinase inhibitor treatment is indicated. The purpose of this prospective study is to determine whether EGFR mutation status could be identified with reference to preoperative factors. Materials and Methods: One hundred-forty eight patients with lung cancer (111 adenocarcinomas, 25 squamous cell carcinomas and 12 other cell types) were enrolled in this study. The EGFR mutation status of each lung cancer was analyzed postoperatively. Results: There were 58 patients with mutant EGFR lung cancers (mutant LC) and 90 patients with wild-type EGFR lung cancers (wild-type LC). There were significant differences in gender, smoking status, maximum tumor diameter in chest CT, type of tumor shadow, clinical stage between mutant LC and wild-type LC. EGFR mutations were detected only in adenocarcinomas. Maximum standardized uptake value (SUVmax:$3.66{\pm}4.53$) in positron emission tomography-computed tomography of mutant LC was significantly lower than that ($8.26{\pm}6.11$) of wild-type LC (p<0.0001). Concerning type of tumor shadow, the percentage of mutant LC was 85.7% (6/7) in lung cancers with pure ground glass opacity (GGO), 65.3%(32/49) in lung cancers with mixed GGO and 21.7%(20/92) in lung cancers with solid shadow (p<0.0001). For the results of discriminant analysis, type of tumor shadow (p=0.00036) was most significantly associated with mutant EGFR. Tumor histology (p=0.0028), smoking status (p=0.0051) and maximum diameter of tumor shadow in chest CT (p=0.047) were also significantly associated with mutant EGFR. The accuracy for evaluating EGFR mutation status by discriminant analysis was 77.0% (114/148). Conclusions: Mutant EGFR is significantly associated with lung cancer with pure or mixed GGO, adenocarcinoma, never-smoker, smaller tumor diameter in chest CT. Preoperatively, EGFR mutation status can be identified correctly in about 77 % of lung cancers.

키워드

참고문헌

  1. Dwamena BA, Sonnad SS, Angobaldo JO, et al (1999). Metastases from non-small cell lung cancer. Mediastinal staging in the 1990s. Meta-analytic comparison of PET and CT. Radiology, 213, 530-6. https://doi.org/10.1148/radiology.213.2.r99nv46530
  2. Hsieh RK, Lim KH, Kuo HT, et al (2005). Female sex and bronchioloalveolar pathologic subtype predict EGFR mutations in non-small cell lung cancer. Chest, 128, 317-21. https://doi.org/10.1378/chest.128.1.317
  3. International Union Against Cancer (2009). TNM classification of malignant tumours. 7th ed. NY, Wiley-Liss, 138-46.
  4. Jorissen RN, Walker F, Pouliot N, et al (2003). Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res, 284, 31-53. https://doi.org/10.1016/S0014-4827(02)00098-8
  5. Kitamura H, Kameda Y, Ito T, Hayashi H (1999). Atypical adenomatous hyperplasia of the lung. Implications for the pathogenesis of peripheral lung adenocarcinoma. Am J Clin Pathol, 111, 610-22.
  6. Le Bihan D, Breton E, Lallemand D, et al (1988). Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiology, 168, 497-505. https://doi.org/10.1148/radiology.168.2.3393671
  7. Lee HY, Lee KS (2011). Ground-glass opacity nodules: histopathology, imaging evaluation, and clinical implications. J Thorac Imaging, 26, 106-18. https://doi.org/10.1097/RTI.0b013e3181fbaa64
  8. Liu WS, Zhao LJ, Pang QS, et al (2014). Prognostic value of epidermal growth factor receptor mutations in resected lung adenocarcinomas. Med Oncol, 31, 771. https://doi.org/10.1007/s12032-013-0771-9
  9. Lynch TJ, Bell DW, Sordella R, et al (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med, 350, 2129-39. https://doi.org/10.1056/NEJMoa040938
  10. Mak RH, Digumarthy SR, Muzikansky A, et al (2011). Role of 18F-fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer. Oncologist, 16, 319-26. https://doi.org/10.1634/theoncologist.2010-0300
  11. Mclntire MG, Santagata S, Ligon K, Chirieac LR (2010). Epidermal growth factor receptor gene amplification in atypical adenomatous hyperplasia of the lung. Am J Transl Res, 2, 309-15.
  12. Miller VA, Kris MG, Shah N, et al (2004). Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol, 22, 1103-9. https://doi.org/10.1200/JCO.2004.08.158
  13. Mori T, Nomori H, Ikeda K, et al (2008). Diffusion-weighted magnetic resonance imaging for diagnosing malignant pulmonary nodules/masses. Comparison with positron emission tomography. J Thoracic Oncol, 3, 358-64. https://doi.org/10.1097/JTO.0b013e318168d9ed
  14. Na II, Byun BH, Kim KM, et al (2010). 18F-FDG uptake and EGFR mutations in patients with non-small cell lung cancer: a single-institution retrospective analysis. Lung Cancer, 67, 76-80. https://doi.org/10.1016/j.lungcan.2009.03.010
  15. Nasu K, Kuroki Y, Kuroki S, et al (2004). Diffusion-weighted single shot echo planar imaging of colorectal cancer using a sensitivity-encoding technique. Jpn J Clin Oncol, 34, 620-26. https://doi.org/10.1093/jjco/hyh108
  16. Paez JG, Janne PA PA, Lee JC, et al (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 304, 1497-500. https://doi.org/10.1126/science.1099314
  17. Pao W, Miller V, Zakowski M, et al (2004). EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA, 101, 13306-11. https://doi.org/10.1073/pnas.0405220101
  18. Raz DJ, He B, Rosell R, Jablons DM (2006). Bronchioloalveolsr carcinoma. A review. Clinical Lung cancer, 7, 313-22. https://doi.org/10.3816/CLC.2006.n.012
  19. Sun PL, Seol H, Lee HJ, et al (2012). High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features. J Thorac Oncol, 7, 323-30. https://doi.org/10.1097/JTO.0b013e3182381515
  20. Tam IYS, Chung LP, Suen WS, et al (2006). Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin Cancer Res, 12, 1647-53. https://doi.org/10.1158/1078-0432.CCR-05-1981
  21. Toloza EM, Harpole L, McCrory DC (2003). Noninvasive staging of non-small cell lung cancer. Chest, 123, 137-46. https://doi.org/10.1378/chest.123.1_suppl.137S
  22. Travis WD, Brambilla E, Noguchi M, et al (2011). International association for the study of lung cancer/ american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol, 6, 244-85. https://doi.org/10.1097/JTO.0b013e318206a221
  23. Usuda K, Zhao XT, Sagawa M, et al (2013). Diffusion-weighted imaging (DWI) signal intensity and distribution represent the amount of cancer cells and their distribution in primary lung cancer. Clinical Imaging, 37, 265-72. https://doi.org/10.1016/j.clinimag.2012.04.026
  24. Yoshizawa A, Motoi N, Riely GJ, et al (2011). Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol, 24, 653-64. https://doi.org/10.1038/modpathol.2010.232

피인용 문헌

  1. Therapeutic Effects and Adverse Drug Reactions are Affected by Icotinib Exposure and CYP2C19 and EGFR Genotypes in Chinese Non-Small Cell Lung Cancer Patients vol.15, pp.17, 2014, https://doi.org/10.7314/APJCP.2014.15.17.7195
  2. Serum Carcinoembryonic Antigen Levels before Initial Treatment are Associated with EGFR Mutations and EML4-ALK Fusion Gene in Lung Adenocarcinoma Patients vol.15, pp.9, 2014, https://doi.org/10.7314/APJCP.2014.15.9.3927
  3. Epidermal Growth Factor Receptor Mutations in Japanese Men with Lung Adenocarcinomas vol.15, pp.24, 2015, https://doi.org/10.7314/APJCP.2014.15.24.10627
  4. Current Drugs and Drug Targets in Non-Small Cell Lung Cancer: Limitations and Opportunities vol.16, pp.10, 2015, https://doi.org/10.7314/APJCP.2015.16.10.4147
  5. KRAS Mutation as a Biomarker for Survival in Patients with Non-Small Cell Lung Cancer, A Meta-Analysis of 12 Randomized Trials vol.16, pp.10, 2015, https://doi.org/10.7314/APJCP.2015.16.10.4439
  6. The Association of EGFR Mutations with Stage at Diagnosis in Lung Adenocarcinomas vol.11, pp.11, 2016, https://doi.org/10.1371/journal.pone.0166821
  7. CT characteristics in pulmonary adenocarcinoma with epidermal growth factor receptor mutation vol.12, pp.9, 2017, https://doi.org/10.1371/journal.pone.0182741
  8. CT characteristics of non-small cell lung cancer with epidermal growth factor receptor mutation: a systematic review and meta-analysis vol.17, pp.1, 2017, https://doi.org/10.1186/s12880-016-0175-3
  9. Associations between clinical data and computed tomography features in patients with epidermal growth factor receptor mutations in lung adenocarcinoma pp.1437-7772, 2017, https://doi.org/10.1007/s10147-017-1197-8
  10. Association between histopathological subtype, 18F-fluorodeoxyglucose uptake and epidermal growth factor receptor mutations in lung adenocarcinoma vol.11, pp.3, 2016, https://doi.org/10.3892/ol.2016.4154
  11. Impact of the epidermal growth factor receptor mutation status on the prognosis of recurrent adenocarcinoma of the lung after curative surgery vol.18, pp.1, 2018, https://doi.org/10.1186/s12885-018-4849-9